New drug aims to prevent Diver's bends
NCT ID NCT06216366
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether an experimental drug called rhu-pGSN can reduce harmful inflammation caused by rapid decompression after high-pressure exposure. Thirty-six healthy, trained divers will be placed in a hyperbaric chamber to simulate a deep dive. Some will receive the drug before or after the exposure, while others get a placebo. Researchers will measure inflammatory markers in the blood and check for symptoms of decompression sickness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
recombinant human plasma gelsolin (rhu-pGSN)
What this could lead to
If it works, this could point toward a treatment to prevent or reduce decompression sickness in divers and others exposed to high pressure.
What could go wrong
This is a small, early-phase trial in healthy divers, not patients. The drug may not reduce inflammation or prevent symptoms, and side effects are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DECOMPRESSION SICKNESS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Maryland School of Medicine
Baltimore, Maryland, 21201, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.